Print |
  • Text A A
  • PDxProstateSubPageGraphic.png

    PTEN by FIsh1

    In prostate cancer, PTEN deletion has been commonly associated with adverse prognosis.

    • PTEN deletions are found in 20% to 40% of Prostate Cancers.
    • Homozygous (deletion of both genes) and Hemizygous (deletion of single gene) characterize particularly aggressive cancers.

    PTEN by FISH… a Prognostic Maker for Both Pre- and Post-Surgical Patients

    PTEN_status.png

    PTEN deletion by FISH may predict PSA biochemical recurrence in post-surgical patients2,3

    PTEN_deletion_graphs.png

    References

    1. Reid AHM, Attard G, Ambroisine L, et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.  British Journal of Cancer. 2010;102(4):678-684.

    2. Krohn A, Diedler T, Burkhardt L, et al.  Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer.  The American Journal of Pathology.  2012;181(2):401–412.

    3. Yoshimoto M, Cunha IW, Coudry RA, et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.  British Journal of Cancer.  2007;97:678-685.

    This test was developed by and its performance characteristics determined by PersonalizeDx. It has not been cleared or approved by the U.S. Food and Drug Administration. PersonalizeDx is a CLIA-accredited laboratory CLIA ID #05D2001811. This test is used for clinical purposes. The clinical validity of the test has been established based upon review of relevant literature. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity testing.